Advertisement


Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130

2023 ASCO Annual Meeting

Advertisement

Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to induction therapy with atezolizumab plus platinum and gemcitabine did not seem to impact overall survival for patients with metastatic urothelial carcinoma. Cisplatin-treated patients appeared to derive a greater benefit with atezolizumab than did carboplatin-treated patients (Abstract 4503).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Enrique Grande, MD: We are here presenting the post-hoc analysis of the IMvigor130 trial about the overall survival according to the response to the induction chemotherapy, based on platinum, that the patient received from this phase-3 trial. As a brief reminder, the IMvigor130 trial was a phase-3 trial, in first-line metastatic urothelial carcinoma patients that were randomized into one of these three arms: chemotherapy, platinum-based chemotherapy, cis/gem, carbo/gem, standard of care at that time; or chemotherapy plus atezolizumab; or another third arm with atezolizumab, the PD-L1 inhibitor, as a single agent. In this post-hoc analysis, we are as considering those patients who were randomized to one of the arms with chemotherapy. They should have received at least four cycles of chemotherapy, of platinum-based chemotherapy. They should have observed a clinical benefit during this induction chemotherapy. It means at least complete response, or partial response, or a stable disease for up to six months on treatment. And they should have also been treated with at least one cycle of maintenance therapy, either with atezolizumab or with placebo matching maintenance therapy. In terms of the overall survival that we got here, the overall survival was counting since week 18, the supposed day one, cycle six of the induction chemotherapy. We analyzed in a retrospective way, two populations: those with a clinical benefit, and those patients in the intention to treat population that progressed during induction chemotherapy. Of course, the prognosis was completely different in between these two populations. What were the main outcomes from this post-hoc analysis? The main outcomes that we observed is that unfortunately, we didn't observe significant difference, clinically speaking and statistically speaking, for those patients we received the combination of chemo plus atezo followed by atezo maintenance, versus those patients in terms of survival that received only chemotherapy. Hazard ratio was 0.84, and the median overall survival in the combination arm followed by the maintenance strategy was 20.5 months, versus 19.6 months in the standard arm. Those patients with the better prognosis, so it means those patients treated with cisplatin, gemcitabine, plus atezolizumab, and those patients with PD-L1 positive expression, they have better prognosis than those patients treated with carbo or those patients with a PD-L1 negative expression in the tumor. But if this is a matter of immunogenicity, we still don't know. We are working on that. The translational research is undergoing this sense. Maybe this is just a matter of prognosis. Another important outcome. What happened in those patients who progressed during the induction chemotherapy? This is the subgroup of patients with the poorest prognosis. The median overall survival for these patients progressing during chemo was only 3.3 months, despite more than 40% of the patients received subsequent lines of treatment, most of them immunotherapy or chemotherapy in the standard control arm. So, there is a clear unmet clinical need on this particular scenario, and it merits to think about if it deserves to give any systemic treatment options for these patients, or at least the current systemic options for these patients that we have so far. Last thing is that the use of enfortumab vedotin, or all their targeted agents like FDFR inhibitors, in this setting was negligible. Very few patients received that, so we cannot really extrapolate or make any conclusion about that. Thank you so much.

Related Videos

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Karim Fizazi, MD, on Prostate Cancer: Phase III Results on Talazoparib Plus Enzalutamide as First-Line Treatment

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer and HRR gene alterations. This regimen also delayed the time to deterioration in global health status and quality of life (Abstract 5004).

Issues in Oncology

Carmen E. Guerra, MD, MSCE, on Diversity, Equity, and Inclusion in Clinical Trials: Expert Commentary

Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).

Lymphoma

Reid Merryman, MD, on High-Risk Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Reid Merryman, MD, of Dana-Farber Cancer Institute, discusses his findings on the regimen of epcoritamab plus rituximab and lenalidomide for patients with high-risk follicular lymphoma. Regardless of whether their disease progressed within 24 months of first-line chemoimmunotherapy, this regimen showed antitumor activity and a manageable safety profile in patients with relapsed or refractory disease. Epcoritamab, a subcutaneous T-cell–engaging bispecific antibody, may abrogate the negative effects of high-risk features (Abstract 7506).

Lymphoma

Manali K. Kamdar, MD, on Primary Refractory and Early Relapsing DLBCL: Therapeutic Options

Manali K. Kamdar, MD, of University of Colorado Hospital, discusses the treatment landscape for the 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) whose disease will relapse. Patients who experience relapse within 1 year of chemoimmunotherapy have poor outcomes with autotransplantation, but chimeric antigen receptor T-cell therapy has shown efficacy and manageable toxicity.

Skin Cancer
Immunotherapy

Jason J. Luke, MD, on Melanoma Adjuvant Therapy: Final Analysis of KEYNOTE-716

Jason J. Luke, MD, of the University of Pittsburgh Medical Center Hillman Cancer Center, discusses adjuvant pembrolizumab, which, in previous results, improved distant metastasis– and recurrence-free survival in patients with resected stage IIB or IIC melanoma vs placebo. After a median follow-up of 39.4 months, adjuvant pembrolizumab continued to show a benefit over placebo, with no new safety signals (Abstract LBA9505).

Advertisement

Advertisement




Advertisement